Cite
Manso L, Moreno F, Márquez R, et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015;22(2):e51-60doi: 10.3747/co.22.2210.
Manso, L., Moreno, F., Márquez, R., Castelo, B., Arcediano, A., Arroyo, M., Ballesteros, A. I., Calvo, I., Echarri, M. J., Enrech, S., Gómez, A., González Del Val, R., López-Miranda, E., Martín-Angulo, M., Martínez-Jañez, N., Olier, C., & Zamora, P. (2015). Use of bevacizumab as a first-line treatment for metastatic breast cancer. Current oncology (Toronto, Ont.), 22(2), e51-60. https://doi.org/10.3747/co.22.2210
Manso, L, et al. "Use of bevacizumab as a first-line treatment for metastatic breast cancer." Current oncology (Toronto, Ont.) vol. 22,2 (2015): e51-60. doi: https://doi.org/10.3747/co.22.2210
Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60. doi: 10.3747/co.22.2210. PMID: 25908921; PMCID: PMC4399624.
Copy
Download .nbib